LOXIGEN, INC.

Biotech · Private

Small molecule lysyl oxidase (LOX) inhibitors for triple negative breast cancer chemoresistance

Grants
$2.5M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Developing novel LOX inhibitors to target chemotherapy resistant TNBC$406,500
Federal grantDepartment of Health and Human Services · Phase II · Developing novel LOX inhibitors to target chemotherapy resistant TNBC$992,932
Federal grantDepartment of Health and Human Services · Phase II · Developing novel LOX inhibitors to target chemotherapy resistant TNBC$1,057,068
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2234Advac Therapeutic LLC——
2235I Peace, Inc.—$47M
2236L.E.A.F. Pharmaceuticals LLC—$40M
2237LOXIGEN, INC.——
2238KAPHA BIO, INC.——
2239Forecast Bio, Inc.—$2.4M
2240Monocacy Therapeutics Inc.—$389K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.